SKINOVATION PHARMACEUTICAL INC Financial Statements (2025 and earlier)

Company Profile

Business Address 440 EAST 400 SOUTH
SALT LAKE CITY, UT 84111
State of Incorp. WY
Fiscal Year End December 31
Industry (SIC) 677 - Blank Checks (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments16,2341632223,55277132
Cash and cash equivalents16,2341632223,55277132
Total current assets:16,2341632223,55277132
Noncurrent Assets
TOTAL ASSETS:16,2341632223,55277132
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities177,414156,477137,793118,173101,94186,269
Interest and dividends payable130,793112,17394,74178,569
Accounts payable6,0006,0007,0006,0007,2007,700
Accrued liabilities171,414150,477    
Debt286,021255,021240,021230,521212,321198,321
Total current liabilities:463,435411,498377,814348,694314,262284,590
Noncurrent Liabilities
Total liabilities:463,435411,498377,814348,694314,262284,590
Equity
Equity, attributable to parent(447,201)(411,335)(377,592)(345,142)(314,185)(284,458)
Common stock708708708708708708
Additional paid in capital25,14825,14825,14825,14825,14825,148
Accumulated deficit(473,057)(437,191)(403,448)(370,998)(340,041)(310,314)
Total equity:(447,201)(411,335)(377,592)(345,142)(314,185)(284,458)
TOTAL LIABILITIES AND EQUITY:16,2341632223,55277132

Income Statement (P&L) (USD)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Operating expenses(14,929)(14,059)(13,830)(13,525)(13,555)(13,415)
Operating loss:(14,929)(14,059)(13,830)(13,525)(13,555)(13,415)
Nonoperating expense
(Other Nonoperating expense)
(20,937)(19,684)(18,620)   
Interest and debt expense(20,937)(19,684)(18,620)(17,432)(16,172)(15,173)
Loss from continuing operations:(56,803)(53,427)(51,070)(30,957)(29,727)(28,588)
Loss before gain (loss) on sale of properties:(51,070)(30,957)(29,727)(28,588)
Net loss:(56,803)(53,427)(51,070)(30,957)(29,727)(28,588)
Other undisclosed net income attributable to parent20,93719,68418,620   
Net loss available to common stockholders, diluted:(35,866)(33,743)(32,450)(30,957)(29,727)(28,588)

Comprehensive Income (USD)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(56,803)(53,427)(51,070)(30,957)(29,727)(28,588)
Comprehensive loss, net of tax, attributable to parent:(56,803)(53,427)(51,070)(30,957)(29,727)(28,588)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: